| Primary |
| Hiv Infection |
66.9% |
| Prophylaxis |
2.8% |
| Drug Exposure During Pregnancy |
2.7% |
| Depression |
2.3% |
| Foetal Exposure During Pregnancy |
2.3% |
| Hepatitis C |
2.1% |
| Antifungal Prophylaxis |
1.9% |
| Convulsion |
1.9% |
| Pathogen Resistance |
1.8% |
| Antiviral Treatment |
1.6% |
| Diabetes Mellitus |
1.6% |
| Mycobacterium Avium Complex Infection |
1.6% |
| Product Used For Unknown Indication |
1.6% |
| Candidiasis |
1.4% |
| Hyperlipidaemia |
1.4% |
| Neuropathy Peripheral |
1.4% |
| Oesophageal Candidiasis |
1.4% |
| Drug Use For Unknown Indication |
1.2% |
| Bipolar Disorder |
1.1% |
| Hypertension |
0.9% |
|
| Pancreatitis |
9.1% |
| Thrombocytopenia |
9.1% |
| Vomiting |
9.1% |
| Blood Creatine Phosphokinase Increased |
5.5% |
| Hepatitis C |
5.5% |
| Pancytopenia |
5.5% |
| Premature Baby |
5.5% |
| Rash |
5.5% |
| Somnolence |
5.5% |
| Accessory Auricle |
3.6% |
| Anaemia |
3.6% |
| Anal Cancer |
3.6% |
| Asthma |
3.6% |
| Drug Hypersensitivity |
3.6% |
| Epistaxis |
3.6% |
| Gastrointestinal Disorder |
3.6% |
| Hepatitis |
3.6% |
| Hodgkin's Disease |
3.6% |
| Hypersensitivity |
3.6% |
| Immune Reconstitution Syndrome |
3.6% |
|
| Secondary |
| Hiv Infection |
69.1% |
| Drug Exposure During Pregnancy |
10.5% |
| Drug Use For Unknown Indication |
6.5% |
| Product Used For Unknown Indication |
2.7% |
| Antiretroviral Therapy |
1.4% |
| Hypertension |
1.3% |
| Gestational Diabetes |
1.1% |
| Pneumocystis Jiroveci Pneumonia |
1.0% |
| Prophylaxis |
0.9% |
| Antifungal Prophylaxis |
0.7% |
| Cough |
0.7% |
| Diarrhoea |
0.6% |
| Mycobacterium Avium Complex Infection |
0.6% |
| Depression |
0.5% |
| Oral Candidiasis |
0.5% |
| Antiviral Treatment |
0.4% |
| Foetal Exposure During Pregnancy |
0.4% |
| Oesophageal Candidiasis |
0.4% |
| Candidiasis |
0.3% |
| Hiv Test Positive |
0.3% |
|
| Progressive External Ophthalmoplegia |
16.3% |
| Umbilical Cord Abnormality |
14.1% |
| Gastrointestinal Malformation |
8.5% |
| Weight Decreased |
7.8% |
| Rhabdomyolysis |
6.2% |
| Premature Labour |
5.6% |
| Visual Impairment |
5.2% |
| Rash |
4.2% |
| Thrombocytopenia |
3.6% |
| Immune Reconstitution Syndrome |
3.3% |
| Hepatitis B |
2.9% |
| Renal Failure Acute |
2.9% |
| Death |
2.6% |
| Polyarthritis |
2.6% |
| Type 2 Diabetes Mellitus |
2.6% |
| Aspartate Aminotransferase Increased |
2.3% |
| Drug Exposure During Pregnancy |
2.3% |
| Osteonecrosis |
2.3% |
| Premature Baby |
2.3% |
| Toxic Epidermal Necrolysis |
2.3% |
|
| Concomitant |
| Hiv Infection |
68.7% |
| Product Used For Unknown Indication |
5.6% |
| Pneumocystis Jiroveci Pneumonia |
4.1% |
| Drug Use For Unknown Indication |
3.7% |
| Hypertension |
2.2% |
| Drug Exposure During Pregnancy |
1.9% |
| Pulmonary Tuberculosis |
1.8% |
| Burkitt's Lymphoma |
1.3% |
| Prophylaxis |
1.2% |
| Cytomegalovirus Oesophagitis |
1.1% |
| Hepatitis B |
1.1% |
| Pain |
1.1% |
| Hepatitis C |
1.0% |
| Mucormycosis |
0.9% |
| Acquired Immunodeficiency Syndrome |
0.8% |
| Antiretroviral Therapy |
0.7% |
| Depression |
0.7% |
| Diabetes Mellitus |
0.7% |
| Polyneuropathy |
0.7% |
| Candidiasis |
0.6% |
|
| Hypokalaemia |
8.1% |
| Thrombocytopenia |
8.1% |
| Myocardial Infarction |
6.5% |
| Pancytopenia |
5.7% |
| Pyrexia |
5.7% |
| Weight Decreased |
5.7% |
| Exomphalos |
4.9% |
| Hodgkin's Disease |
4.9% |
| Pulmonary Embolism |
4.9% |
| Suicidal Ideation |
4.9% |
| Abortion Spontaneous |
4.1% |
| Adenocarcinoma |
4.1% |
| Coronary Artery Disease |
4.1% |
| Hypertensive Crisis |
4.1% |
| Loss Of Consciousness |
4.1% |
| Off Label Use |
4.1% |
| Renal Tubular Disorder |
4.1% |
| Rhabdomyolysis |
4.1% |
| Toxic Epidermal Necrolysis |
4.1% |
| Weight Increased |
4.1% |
|
| Interacting |
| Hiv Infection |
39.4% |
| Deep Vein Thrombosis |
15.2% |
| Hiv Test Positive |
15.2% |
| Product Used For Unknown Indication |
12.1% |
| Aspergillosis |
6.1% |
| Convulsion |
6.1% |
| Oesophagitis |
6.1% |
|
| Drug Interaction |
37.5% |
| Rash Maculo-papular |
25.0% |
| Neuropathy Peripheral |
12.5% |
| Somnolence |
12.5% |
| Therapy Regimen Changed |
12.5% |
|
